NEW YORK (GenomeWeb News) – BGI-Shenzhen has extended its cash tender offer for Complete Genomics again, BGI announced late Friday.
The deal is now set to expire midnight EST, Feb. 1. It had been previously extended until midnight EST, Jan. 25.
The depositary for the offer has indicated that about 30,949,757 shares, or 87 percent, of Complete's common stock, have been validly tendered and not withdrawn. The $118 million deal has met various regulatory approvals, but a week ago BGI said that China's Ministry of Commerce and the State Administration of Foreign Exchange had not yet approved the acquisition. It did not update the status of those reviews on Friday.